Title |
Clinical outcomes in patients with node-negative breast cancer treated based on the recurrence score results: evidence from a large prospectively designed registry
|
---|---|
Published in |
npj Breast Cancer, September 2017
|
DOI | 10.1038/s41523-017-0034-6 |
Pubmed ID | |
Authors |
Salomon M. Stemmer, Mariana Steiner, Shulamith Rizel, Lior Soussan-Gutman, Noa Ben-Baruch, Avital Bareket-Samish, David B. Geffen, Bella Nisenbaum, Kevin Isaacs, Georgeta Fried, Ora Rosengarten, Beatrice Uziely, Christer Svedman, Debbie McCullough, Tara Maddala, Shmuel H. Klang, Jamal Zidan, Larisa Ryvo, Bella Kaufman, Ella Evron, Natalya Karminsky, Hadassah Goldberg, Steven Shak, Nicky Liebermann |
Abstract |
The 21-gene Recurrence Score® (RS) assay is a validated prognostic/predictive tool in ER + early-stage breast cancer. However, clinical outcome data from prospective studies in RS ≥ 11 patients are lacking, as are relevant real-life clinical practice data. In this retrospective analysis of a prospectively designed registry, we evaluated treatments/clinical outcomes in patients undergoing RS-testing through Clalit Health Services. The analysis included N0 ER + HER2-negative breast cancer patients who were RS-tested from 1/2006 through 12/2010. Medical records were reviewed to verify treatments/recurrences/survival. The cohort included 1801 patients (median follow-up, 6.2 years). Median age was 60 years, 50.4% were grade 2 and 81.1% had invasive ductal carcinoma; 48.9% had RS < 18, 40.7% RS 18-30, and 10.4% RS ≥ 31, with chemotherapy use of 1.4, 23.7, and 87.2%, respectively. The 5-year Kaplan-Meier estimates for distant recurrence were 0.8, 3.0, and 8.6%, for patients with RS < 18, RS 18-30 and RS ≥ 31, respectively; the corresponding 5-year Kaplan-Meier estimates for breast cancer death were 0.0, 0.9, and 6.2%. Chemotherapy-untreated patients with RS < 11 (n = 304) and 11-25 (n = 1037) (TAILORx categorization) had 5-year Kaplan-Meier estimates for distant recurrence risk/breast cancer death of 1.0%/0.0% and 1.3%/0.4%, respectively. Our results extend those of the prospective TAILORx trial: the 5-year Kaplan-Meier estimates for distant recurrence and breast cancer death rate for the RS < 18 patients were very low supporting the use of endocrine therapy alone. Furthermore, in chemotherapy-untreated patients with RS 11-25 (where TAILORx patients were randomized to chemoendocrine or endocrine therapy alone), 5-year distant recurrence rates were also very low, suggesting that chemotherapy would not have conferred clinically meaningful benefit. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 2 | 40% |
Unknown | 3 | 60% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 5 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 58 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 9 | 16% |
Other | 4 | 7% |
Student > Master | 4 | 7% |
Student > Ph. D. Student | 3 | 5% |
Student > Doctoral Student | 3 | 5% |
Other | 5 | 9% |
Unknown | 30 | 52% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 12 | 21% |
Biochemistry, Genetics and Molecular Biology | 6 | 10% |
Nursing and Health Professions | 2 | 3% |
Agricultural and Biological Sciences | 2 | 3% |
Chemical Engineering | 1 | 2% |
Other | 4 | 7% |
Unknown | 31 | 53% |